SCHEMBL1012283

SCHEMBL1012283

COc1ccc(CNc2ncc(C(=O)NC3CCCC3)c(C)n2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TYRO3 Q06418 3/20 0.54
RAB9A P51151 3/20 0.53
NPC1 O15118 2/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
CNR2 P34972 2/20 0.51
ABHD6 Q9BV23 1/20 0.51
EPHX2 P34913 1/20 0.50
CNR1 P21554 2/20 0.49
CHEK1 O14757 1/20 0.49
IKBKB O14920 1/20 0.49
AURKA O14965 1/20 0.49
PAK4 O96013 1/20 0.49
CHEK2 O96017 1/20 0.49
ABL1 P00519 1/20 0.49
EGFR P00533 1/20 0.49
INSR P06213 1/20 0.49
LCK P06239 1/20 0.49
FGFR1 P11362 1/20 0.49
SELP P16109 1/20 0.49
CSNK2A2 P19784 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1013775 0.99 NPC1 (0.55) TYRO3RAB9ANPC1SMN1; SMN2CNR2
SCHEMBL1015199 0.99 NPC1 (0.55) TYRO3RAB9ANPC1SMN1; SMN2CNR2
SCHEMBL1015261 0.88 TYRO3 (0.54) TYRO3RAB9ASMN1; SMN2CHEK1IKBKB
SCHEMBL1014954 0.87 TYRO3 (0.53) TYRO3RAB9ANPC1SMN1; SMN2CHEK1
SCHEMBL1015521 0.87 TYRO3 (0.53) TYRO3RAB9ANPC1SMN1; SMN2CHEK1
SCHEMBL1013869 0.87 RAB9A (0.60) TYRO3RAB9ANPC1SMN1; SMN2CNR2
SCHEMBL1014913 0.86 RAB9A (0.58) TYRO3RAB9ANPC1SMN1; SMN2CNR2
SCHEMBL1015403 0.86 RAB9A (0.58) TYRO3RAB9ANPC1SMN1; SMN2CNR2
SCHEMBL1015098 0.82 TYRO3 (0.70) TYRO3RAB9ACHEK1IKBKBAURKA
SCHEMBL1016069 0.81 TYRO3 (0.69) TYRO3RAB9ACHEK1IKBKBAURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2271629-A1 SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 AstraZeneca AB (SE) 2011-01-12 EP disclosed
WO-2009130496-A1 SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 ASTRAZENECA AB (SE) 2009-10-29 WO disclosed
US-20090264401-A1 SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 ASTRAZENECA AB (SE) 2009-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264401-A1 SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 CYP2S1, HSD11B1, HSD3B1 TYRO3 4281/4885RAB9A 1947/4885NPC1 1075/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.